This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Harker, W. G. Articles by Trent, J. M. Search for Related Content PubMed PubMed Citation Articles by Harker, W. G. Articles by Trent, J. M.

Multidrug Resistance in Mitoxantrone-selected HL-60 Leukemia Cells in the Absence of P-Glycoprotein Overexpression¹

Department of Medicine, University of Utah School of Medicine and Veterans Administration Medical Center, Salt Lake City, Utah 84132 [W. G. H., D. L. S.], and Departments of Medicine [W. S. D.] and Radiation Oncology [P. S. M., J. M. T.], The University of Arizona, Tucson, Arizona 85724

A multidrug-resistant variant of the human HL-60 promyelocytic leukemia cell line (HL-60/MX2) has been isolated in vitro by subculturing these cells in progressively increasing concentrations of mitoxantrone. The MX2 cells are cross-resistant to etoposide, teniposide, bisantrene, dactinomycin, 4'-(9-acridinylamino)methanesulfon-m-anisidide, and the anthracyclines daunorubicin and doxorubicin but retain sensitivity to the Vinca alkaloids melphalan and mitomycin C. In addition, the MX2 cells display slight collateral sensitivity to bleomycin. Despite being 30–35-fold less sensitive to mitoxantrone, net [¹⁴C]mitoxantrone accumulation at 60 min was reduced by only 10% in the mitoxantrone-resistant cells compared to the parental line. Furthermore, at later time points, e.g., 120 and 180 min, mitoxantrone accumulation in the MX2 cells exceeded that in HL-60 cells by 8.5 and 6.4%, respectively. No significant differences were observed between the sensitive and resistant cell lines in the initial (first 60 s) accumulation of mitoxantrone, and only minor (3–6%) enhancement of mitoxantrone efflux was detected in the resistant cell type. Monoclonal antibodies to P-glycoprotein had no detectable reactivity with membrane vesicles from either the sensitive or resistant cell types as determined by standard immunoblotting techniques. The mitoxantrone-resistant cells displayed a reciprocal translocation [rcpt(1;3)-(q21;p23)] not found in the sensitive parent, but there were no demonstrable double minute chromosomes or homogeneous staining regions in cells from either line. Thus, these mitoxantrone-resistant human leukemia cells display many features which are atypical for the "classic" multidrug resistance phenotype and should provide a useful model for the study of multidrug resistance which is not mediated by P-glycoprotein.

¹ Supported by Veterans Administration Medical Research and USPHS Grants CA-43043 (W. S. D.) and CA-41183 (P. S. M., J. M. T.).

² To whom requests for reprints should be addressed at Medical Service 111C, VA Medical Center, Salt Lake City, UT 84148.

Received 1/16/89. Revised 4/28/89. Accepted 5/ 3/89.

This article has been cited by other articles:

				L. A. Hazlehurst, R. F. Argilagos, M. Emmons, D. Boulware, C. A. Beam, D. M. Sullivan, and W. S. Dalton Cell Adhesion to Fibronectin (CAM-DR) Influences Acquired Mitoxantrone Resistance in U937 Cells Cancer Res., February 15, 2006; 66(4): 2338 - 2345. [Abstract] [Full Text] [PDF]

				R. J. Ward and C. Autexier Pharmacological Telomerase Inhibition Can Sensitize Drug-Resistant and Drug-Sensitive Cells to Chemotherapeutic Treatment Mol. Pharmacol., September 1, 2005; 68(3): 779 - 786. [Abstract] [Full Text] [PDF]

				V. S. Donnenberg and A. D. Donnenberg Multiple Drug Resistance in Cancer Revisited: The Cancer Stem Cell Hypothesis J. Clin. Pharmacol., August 1, 2005; 45(8): 872 - 877. [Abstract] [Full Text] [PDF]

				A. C. Lockhart, R. G. Tirona, and R. B. Kim Pharmacogenetics of ATP-binding Cassette Transporters in Cancer and Chemotherapy Mol. Cancer Ther., July 1, 2003; 2(7): 685 - 698. [Abstract] [Full Text] [PDF]

				T Litman, M Brangi, E Hudson, P Fetsch, A Abati, D. Ross, K Miyake, J. Resau, and S. Bates The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2) J. Cell Sci., January 6, 2000; 113(11): 2011 - 2021. [Abstract] [PDF]

				D. D. Ross, W. Yang, L. V. Abruzzo, W. S. Dalton, E. Schneider, H. Lage, M. Dietel, L. Greenberger, S. P. C. Cole, and L. A. Doyle Atypical Multidrug Resistance: Breast Cancer Resistance Protein Messenger RNA Expression in Mitoxantrone-Selected Cell Lines J Natl Cancer Inst, March 3, 1999; 91(5): 429 - 433. [Abstract] [Full Text] [PDF]

				L. A. Hazlehurst, N. E. Foley, M. C. Gleason-Guzman, M. P. Hacker, A. E. Cress, L. W. Greenberger, M. C. De Jong, and W. S. Dalton Multiple Mechanisms Confer Drug Resistance to Mitoxantrone in the Human 8226 Myeloma Cell Line Cancer Res., March 1, 1999; 59(5): 1021 - 1028. [Abstract] [Full Text] [PDF]

				M. P. Boland, K. A. Fitzgerald, and L. A. J. O'Neill Topoisomerase II Is Required for Mitoxantrone to Signal Nuclear Factor kappa B Activation in HL60 Cells J. Biol. Chem., August 11, 2000; 275(33): 25231 - 25238. [Abstract] [Full Text] [PDF]

				S.-P. Sim and L. F. Liu Nucleolytic Cleavage of the Mixed Lineage Leukemia Breakpoint Cluster Region during Apoptosis J. Biol. Chem., August 17, 2001; 276(34): 31590 - 31595. [Abstract] [Full Text] [PDF]